Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.
Recombinant Human GM-CSF Protein (HEK293 Cells) (His Tag)(Active)
£802.40 – £5,731.20 excluding VAT
Size | 100µg, 1mg |
---|---|
Active Protein | Active protein |
Activity | Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 0.1-0.6 ng/mL. |
Protein Construction | A DNA sequence encoding the mature form of human GM-CSF (NP_000749.2) (Ala 18-Glu 144) was expressed, with a polyhistidine tag at the N-terminus. |
Sequence | Ala18-Glu144 |
Fusion Tag | N-His |
Accession | NP_000749.2 |
Species | Human |
Expressed Host | HEK293 Cells |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Purity | > 92 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Stability and Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Mol Mass | 16.9 kDa |
AP Mol Mass | 24-27 kDa |
Formulation | Lyophilized from sterile PBS, pH 7.4.Normally 5 % – 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.Please refer to the specific buffer information in the printed manual. |
Research Areas | immunology |
Reconstitution | Please refer to the printed manual for detailed information. |
Related Product
Related products
-
Protein
Recombinant ZIKV (strain Zika SPH2015) NS5 protein (His Tag)
£363.20 – £855.00 excluding VAT -
Protein
Recombinant ZIKV (strain Zika SPH2016) Stem/anchor domain of flavivirus envelope glycoprotein E protein (Fc Tag)
£540.00 – £855.00 excluding VAT